Pharmaceutical application of radix scrophulariae extract
By preparing Scrophularia ningpoensis extract as a drug for liver fibrosis, inhibiting liver collagen deposition and fibrosis-related gene expression, the problem of lack of effective treatment drugs for liver fibrosis has been solved, and effective prevention and treatment of chemical liver fibrosis has been achieved.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- JINLING PHARMA
- Filing Date
- 2024-11-19
- Publication Date
- 2026-05-19
AI Technical Summary
Currently, there are no effective chemical drugs and biological agents to treat and prevent liver fibrosis. Liver transplantation is the only treatment option. Moreover, the pathogenesis of liver fibrosis is complex, and the pharmacological activity of the traditional Chinese medicine Scrophularia ningpoensis has not been fully utilized in the treatment of liver fibrosis.
Scrophularia extract was prepared into pharmaceutically acceptable oral or injectable dosage forms. It was used to prevent and treat chemical liver fibrosis by inhibiting collagen deposition in the liver, reducing the content of hydroxyproline in liver tissue and the content of hyaluronic acid and type IV collagen in serum.
Scrophularia extract significantly reduced the degree of liver fibrosis, decreased collagen deposition in the liver, reduced the content of related markers in liver tissue and serum, and inhibited the expression of fibrosis genes in animal experiments, showing good therapeutic and preventive effects on liver fibrosis.
Smart Images
Figure CN122056956A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the pharmaceutical field and relates to the pharmaceutical use of Scrophularia ningpoensis extract, specifically to the use of Scrophularia ningpoensis extract in the preparation of drugs for the prevention and / or treatment of liver fibrosis, and particularly to the use of Scrophularia ningpoensis extract in the preparation of drugs for the prevention and / or treatment of chemical liver fibrosis. Background Technology
[0002] Liver fibrosis is a persistent process of liver damage and repair following various forms of chronic liver injury. This repeated process leads to excessive and abnormal deposition of extracellular matrix (ECM) in the liver. In the early stages of liver fibrosis, the symptoms can be reversed if the underlying cause of liver damage is eliminated. However, without effective treatment, chronic liver damage cannot be improved, and the process of liver damage and repair continues, eventually leading to cirrhosis and even liver cancer. The pathogenesis of liver fibrosis is complex, involving different cell types and signaling pathways in the liver, and the mechanisms are not yet fully understood. Therefore, its treatment remains a major challenge in international medicine. Although the pathogenesis of liver fibrosis is complex, excessive activation of hepatic stellate cells (HSCs) is recognized as a core event in the development and progression of liver fibrosis. It has been reported that the incidence of liver fibrosis in people with different types of chronic liver disease is 18%–27%, and approximately 1.2 million people die from cirrhosis and 810,000 from liver cancer worldwide each year. Currently, there are no universally recognized, specific, and effective chemical drugs or biological agents for the prevention and treatment of liver fibrosis. Liver transplantation is the only treatment option for decompensated liver disease. Therefore, finding drugs that can effectively inhibit or improve liver fibrosis is of great significance.
[0003] Scrophularia, a traditional Chinese medicine, is the dried root of the plant Scrophularia ningpoensis Hemsl., belonging to the Scrophulariaceae family. Its properties are sweet, bitter, and salty, with a slightly cold nature. Its main functions are clearing heat and cooling the blood, nourishing yin and reducing fire, and detoxifying and dispersing nodules. It is used for heat entering the blood level, febrile diseases with rashes, yin deficiency due to febrile diseases, red tongue with thirst, constipation due to fluid depletion, steaming cough due to bone heat, red eyes, sore throat, diphtheria, scrofula, carbuncles, and boils. Research reports indicate that Scrophularia contains terpenes, phenylpropanoids, organic acids, volatile oils, steroids, sugars, flavonoids, alkaloids, phenols, and other chemical components, thus possessing rich pharmacological activities such as anti-inflammatory, antioxidant, anti-tumor, anti-fatigue, uric acid-lowering, antidepressant, and cardioprotective effects. It is still used to treat fever, swelling, constipation, pharyngitis, laryngitis, neuritis, sore throat, rheumatism, and arthritis. Summary of the Invention
[0004] The purpose of this invention is to provide new medicinal uses for Scrophularia ningpoensis.
[0005] Use of Scrophularia ningpoensis extract in the preparation of medicines for the prevention and / or treatment of liver fibrosis.
[0006] The liver fibrosis described herein is characterized by at least one of the following: increased collagen deposition in the liver, elevated hydroxyproline content in liver tissue, elevated serum hyaluronic acid, elevated serum type IV collagen, and increased expression of fibrosis and collagen deposition-related genes.
[0007] Specifically, the liver fibrosis mentioned is chemical liver fibrosis.
[0008] More specifically, the aforementioned chemical liver injury is carbon tetrachloride-induced liver fibrosis.
[0009] Preferably, the use is the use of Scrophularia ningpoensis extract in the preparation of a medicament for the prevention and / or treatment of liver fibrosis by inhibiting liver collagen deposition, reducing hydroxyproline content in liver tissue, reducing serum hyaluronic acid content, reducing serum type IV collagen content, and inhibiting the expression of fibrosis and collagen deposition-related genes.
[0010] The dosage form of the drug is a pharmaceutically acceptable oral dosage form or injectable formulation.
[0011] The oral preparations are oral solid preparations and oral liquid preparations; the oral solid preparations are tablets, sustained-release tablets, dispersible tablets, lozenges, capsules, sustained-release capsules, granules, suspensions, drops, and pills; the oral liquid preparations are mixtures, emulsions, suspensions, drops, or syrups; the injectable preparations are injection solutions or powder injections.
[0012] The pharmaceutical excipients are selected from one or more of flavoring agents, clarifying agents, and preservatives. The flavoring agents are selected from one or more of sucrose, lactose, other sugars, polyols (such as sorbitol, glycerin, etc.), citric acid, sodium saccharin, aspartame, cyclamate, and steviol glycosides. The clarifying agents are selected from one or more of sugar, sucrose, sorbitol, sucralose, sodium saccharin, sodium cyclophosphamide, aspartame, neotame, acetylsupan potassium, and steviol glycosides. The preservatives are selected from one or more of benzoic acid, sorbic acid, formic acid, propionic acid or their salts (such as sodium benzoate, potassium sorbate, etc.), and parabens such as methylparaben, ethylparaben, propylparaben, and butylparaben.
[0013] The pharmaceutical excipients mentioned include, but are not limited to: lecithin, aluminum stearate, alumina, ion exchange materials, self-emulsifying drug delivery systems, Tween or other surfactants, serum proteins, buffering substances such as phosphates, glycine, sorbic acid, water, salts, electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, magnesium silicate, and mixtures of saturated fatty acid glycerides.
[0014] The pharmaceutical excipients also include binders (such as microcrystalline cellulose), fillers (such as starch, glucose, anhydrous lactose and lactose beads), disintegrants (such as cross-linked PVP, cross-linked sodium carboxymethyl starch, cross-linked sodium carboxymethyl cellulose, and low-substituted hydroxypropyl cellulose), lubricants (such as magnesium stearate), as well as absorption promoters, adsorbents, excipients, diluents, wetting agents, etc.
[0015] Use of Scrophularia ningpoensis extract in the preparation of health products that have an auxiliary protective effect against chemically induced liver damage.
[0016] The aforementioned chemical liver injury is characterized by at least one of the following: increased liver collagen deposition, elevated hydroxyproline content in liver tissue, elevated serum hyaluronic acid, elevated serum type IV collagen, and increased expression of fibrosis and collagen deposition-related genes.
[0017] The health supplement is in a pharmaceutically acceptable oral dosage form.
[0018] The oral preparations mentioned include tablets, lozenges, capsules, granules, suspensions, drops, pills, oral liquids, tea, fruit juice, and beverages.
[0019] The genes related to fibrosis and collagen deposition are Acta2, Col1a1, and Col3a1.
[0020] The aforementioned Scrophularia extract is an aqueous extract or an aqueous alcohol precipitate of Scrophularia.
[0021] The Scrophularia extract is prepared by the following method: soaking in water, decocting 2-4 times, filtering, combining the filtrates, concentrating the filtrate, adding water to a crude drug concentration of 0.5-1.5 g / mL, refrigerating, and filtering; or soaking Scrophularia in water, decocting 2-4 times, filtering, combining the filtrates, concentrating the filtrate, adding ethanol to a concentration of 60%-70%, allowing to stand, taking the supernatant, recovering the ethanol until no alcohol odor is detected, adding ethanol again to a concentration of 75%-85%, allowing to stand, taking the supernatant, recovering the ethanol until no alcohol odor is detected, adding water to a crude drug concentration of 0.5-1.5 g / mL, refrigerating, and filtering.
[0022] Preferably, the Scrophularia extract is prepared by the following method: soaking in water, decocting twice, filtering, combining the filtrates, concentrating the filtrate, adding water to a crude drug concentration of 0.85 g / mL, refrigerating, and filtering; or soaking Scrophularia in water, decocting twice, filtering, combining the filtrates, concentrating the filtrate, adding ethanol to a concentration of 66%, allowing it to stand, taking the supernatant, recovering the ethanol until there is no alcohol odor, adding ethanol again to a concentration of 80%, allowing it to stand, taking the supernatant, recovering the ethanol until there is no alcohol odor, adding water to a crude drug concentration of 0.85 g / mL, refrigerating, and filtering.
[0023] Preferably, each time of decocting, the material-liquid ratio of the scrophulariae and water is 1:3-1:10 g / mL.
[0024] Preferably, the filtrate is concentrated to a relative density of 1.16 (80 °C).
[0025] Preferably, the temperature for refrigeration is -4 °C.
[0026] Advantages of the present invention:
[0027] It is found at the animal level in the present invention that the scrophulariae extract can reduce liver fibrosis such as carbon tetrachloride-induced chemical liver fibrosis, reduce liver collagen deposition, decrease the content of hydroxyproline in liver tissue, reduce the increased contents of HA and Col IV in serum, and decrease the expression of genes related to fibrosis and collagen deposition, and has a good effect in treating or preventing liver fibrosis. Description of the drawings
[0028] Figure 1 They are the results of Masson and Sirius Red staining of liver tissue.
[0029] Figure 2 They are the results of Real-Time PCR. Detailed implementation manners
[0030] The technical solution of the present invention is described in detail in specific implementation manners. Through the description of specific implementation manners, the features, purposes and advantages of the present invention will be more obvious.
[0031] Example 1
[0032] The carbon tetrachloride (CCl4)-induced mouse liver fibrosis model is an animal experimental model widely used in liver fibrosis research. Therefore, the present invention uses the CCl4-induced mouse liver fibrosis animal model to evaluate the therapeutic effect of the scrophulariae extract on liver fibrosis.
[0033] 1.1 Experimental materials
[0034] 1.1.1 Experimental animals
[0035] Male clean-grade C57BL / 6J mice, weighing 18-20 g, were purchased from Shanghai Slake Experimental Animal Co., Ltd. [Certificate number: SYXK (Shanghai) 2020-0009], and were raised in the Experimental Animal Center of Shanghai University of Traditional Chinese Medicine. The feeding temperature of the mice was (22±1) °C, the relative humidity was (65±10)%, and the light was cycled for 12 h / 12 h.
[0036] 1.1.2 Drugs
[0037] Test drug: Scrophularia extract is a water-extracted alcohol precipitate prepared from Scrophularia ningpoensis (purchased from a medicinal herb market and identified as genuine). The specific process is as follows: Take 850g of Scrophularia ningpoensis, add 6 times the amount of water (5100mL) and soak for 2 hours. Decoction twice, with a material-to-liquid ratio of 1:6g / mL each time, and decoction for 1.5 hours each time. Filter, combine the filtrates, and concentrate the filtrate to a concentrated extract (relative density 1.16 at 80℃). Add an appropriate amount of ethanol to a concentration of 66% alcohol, let stand, take the supernatant, and concentrate under reduced pressure to recover the ethanol until a concentrated extract without alcohol odor is obtained. Add ethanol to a concentration of 80% alcohol, let stand, take the supernatant, concentrate under reduced pressure to recover the ethanol until no alcohol odor is obtained, add water to 1000mL to make the crude drug concentration 0.85g / mL, refrigerate at -4℃, and filter to obtain the final product.
[0038] Positive test result: Silymarin (SIL) was purchased from Shanghai Yuanye Biotechnology.
[0039] 1.2 Experimental Methods
[0040] 1.2.1 Animal Experiment Protocol
[0041] Male C57BL / 6 mice were randomly divided into 5 groups, with 5 mice in each group. The groups were: Control group (blank control); CCl4 group (model group); CCl4+SIL group (positive control group, administered at 200 mg / kg, prepared as a suspension using double-distilled water, administered by gavage); CCl4+Scrophularia extract low-dose group (3.9 mL / kg extract, equivalent to 3.32 g / kg raw herb, administered by gavage); and CCl4+Scrophularia extract high-dose group (11.7 mL / kg extract, equivalent to 9.95 g / kg raw herb, administered by gavage). After one week of acclimatization, except for the normal Control group mice, the other mice were intraperitoneally injected with a CCl4-ol-ol mixture (CCl4 dissolved in olive oil at a volume ratio of 1:3), with a CCl4 dose of 2 mL / kg. One week later, mice injected intraperitoneally with CCl4 were randomly and evenly divided into four groups: a CCl4 group, a CCl4 + SIL group, a low-dose CCl4 + Scrophularia ningpoensis extract group, and a high-dose CCl4 + Scrophularia ningpoensis extract group. All four groups received daily drug intervention, while the control group received an equal volume of double-distilled water. The drug administration continued for three weeks. Blood was collected from the orbital cavity after anesthesia, and the animals were euthanized by cervical dislocation. Liver tissue was then harvested, flash-frozen in liquid nitrogen, and stored at -80°C for later use.
[0042] 1.2.2 Observation of Masson and Sirius Red staining in liver tissue
[0043] Liver tissues from the same location (liver lobule) of mice were taken for pathological examination. The tissues were fixed with 4% paraformaldehyde solution, embedded in paraffin, sectioned, and stained with Masson and Sirius Red. The liver morphological changes in each group were evaluated under an optical microscope.
[0044] 1.2.3 Detection of hydroxyproline (HYP) content in liver tissue
[0045] Accurately weigh 50 mg of liver tissue sample and add 0.5 mL of hydrolysis buffer, then mix well. Cap the sample and hydrolyze at 95°C for 20 min. Add 0.5 mL of pH adjustment solution A to each tube, mix well, then adjust the pH to 6.0–6.8 with pH adjustment solution B, and then add double-distilled water to a final volume of 5 mL, mixing well. Take 0.5 mL of the diluted hydrolysis buffer, mix with activated charcoal, centrifuge at 3500 × g for 10 min, and collect 0.25 mL of the supernatant. Add reagents I, II, and III according to the instructions of the hydroxyproline (HYP) assay kit (alkaline hydrolysis method) from Nanjing Jiancheng Biotechnology Co., Ltd., mix well, incubate at 60°C for 15 min, cool to room temperature, centrifuge at 3500 × g for 10 min, collect the supernatant, and measure the absorbance at 550 nm. Calculate the hydroxyproline content in the liver tissue.
[0046] Hydroxyproline content = (Measured OD value - Blank OD value) ÷ (Standard OD value - Blank OD value) × Standard concentration (5 μg / mL) × (Total volume of hydrolysate ÷ Tissue wet weight);
[0047] The blank OD value is the absorbance of double-distilled water measured at 550 nm after the experiment was conducted according to the kit requirements. The standard OD value is the absorbance of 5 μg / mL hydroxyproline standard provided by the kit measured at 550 nm after the experiment was conducted according to the kit requirements.
[0048] 1.2.4 Detection of serum hyaluronic acid (HA) and collagen type IV (Col IV) levels
[0049] Mouse serum was collected, and the levels of HA and Col IV in mouse serum were detected using the Shanghai Weiao Biotechnology ELISA kit according to the kit instructions, employing an antibody sandwich method. The procedure is summarized as follows: Samples and standards were added to a pre-coated ELISA plate, incubated at 37°C for 50 minutes, and washed three times; biotinylated detection antibody was added, incubated at 37°C for 50 minutes, and washed three times; SABC complex was added, incubated at 37°C for 30 minutes, and washed three times; TMB chromogenic solution was added, incubated at 37°C for 10-20 minutes, and stop solution was added. The ELISA plate was placed in an ELISA reader, and the absorbance was measured at 450 nm. A standard curve was plotted with standard concentration on the x-axis and OD value on the y-axis. The levels of HA and Col IV in the sample were calculated based on the sample OD value and the standard curve. 1.2.5 Detection of mRNA expression in liver tissue
[0050] Total RNA extraction: 15 mg of liver tissue was cut and placed in a 1.5 mL centrifuge tube. 1 mL of Trizol homogenate was added and the mixture was incubated on ice for 5 min. 200 μL of chloroform was added and shaken for 15 s. The mixture was centrifuged at 12000 × g for 15 min at 4 °C. The colorless aqueous layer was transferred to a new tube and 250 μL of isopropanol was added. The mixture was shaken thoroughly and incubated for 10 min. The mixture was centrifuged at 12000 × g for 10 min at 4 °C to obtain RNA precipitate. The supernatant was discarded. 1 mL of pre-cooled 75% ethanol was added and the mixture was centrifuged at 7500 × g for 5 min at 4 °C. After centrifugation, the ethanol was discarded. After the precipitate was dried, 200 μL of DEPC water was added to dissolve it completely. The resulting RNA solution was used to determine the RNA concentration in each sample. The solution was stored at -80 °C for later use.
[0051] Reverse transcription: Prepare the reverse transcription system by adding the appropriate reagents according to the kit instructions and mixing thoroughly. Incubate at 37℃ for 30 min, then at 85℃ for 1 min. Perform reverse transcription according to this temperature program. After reverse transcription, store the cDNA sample at -80℃ for later use.
[0052] Real-time PCR: Prepare the reaction mixture according to the kit instructions, with a loading volume of 10 μL. Perform real-time PCR amplification experiments according to the instrument instructions. 2 -ΔΔ Ct method to calculate gene expression differences between two groups.
[0053] Table 1. Primer sequences
[0054]
[0055] 1.2.6 Data Statistics
[0056] Experimental data are expressed as mean ± standard deviation (Mean ± SD) and analyzed using SPSS 16.0 software. One-way ANOVA was used for analysis of variance between groups. Compared with the blank control group,* P<0.05, ** P<0.01, *** P<0.001; compared with the model group, # P<0.05, ## P<0.01, ### P<0.001.
[0057] 1.3 Experimental Results
[0058] 1.3.1 Effects of Scrophularia ningpoensis extract on collagen deposition in liver tissue of mice with CCl4-induced liver fibrosis
[0059] Masson staining and Serius Red staining results of liver tissue are shown in the figure. Figure 1 CCl4 can cause significant collagen deposition in the liver of mice, starting in the portal area and spreading outward, bridging with collagen in adjacent portal areas to form obvious fibrous septa, completely isolating the liver lobules; SIL (200 mg / kg) can reduce CCl4-induced collagen deposition, but the liver lobules are not completely isolated, and some "portal-portal" bridging fibrous septa still exist; low-dose Scrophularia extract (3.32 g / kg) has the same efficacy as SIL, while high-dose Scrophularia extract (9.95 g / kg) has better efficacy than SIL, with collagen deposition only appearing around the portal area, and no bridging fibrous septa forming in adjacent areas.
[0060] 1.3.2 Scrophularia extract reduced the elevated HYP content in the liver tissue of mice with CCl4-induced liver fibrosis.
[0061] The experimental results are shown in Table 2. Compared with the blank control group, the HYP content in the liver of mice in the CCl4 group was significantly increased (P<0.01), and high-dose Scrophularia extract (9.95g / kg) could reduce the CCl4-induced increase in HYP content in the liver of mice (P<0.05).
[0062] Table 2. Effects of Scrophularia ningpoensis extract on HYP content in CCl4-induced elevated liver tissue of mice.
[0063]
[0064] Note: Compared with the blank control group ** P<0.01; compared with the CCl4 group, # P<0.01; n=5.
[0065] 1.3.3 Scrophularia extract reduced the elevated HA and Col IV levels in the serum of mice with CCl4-induced liver fibrosis.
[0066] The ELISA results are shown in Table 3. Compared to the blank control group, the serum HA content in the CCl4 group was significantly increased (P<0.01), while different doses of Scrophularia ningpoensis extract (3.32, 9.95 g / kg) significantly reduced the CCl4-induced increase in HA content (P<0.01). Similarly, compared to the blank control group, the serum Col IV content in the CCl4 group was significantly increased (P<0.01), while different doses of Scrophularia ningpoensis extract (3.32, 9.95 g / kg) significantly reduced the CCl4-induced increase in Col IV content (P<0.01).
[0067] Table 3. Effects of Scrophularia ningpoensis extract on serum HA and Col IV levels in CCl4-induced elevated mice.
[0068]
[0069] Note: Compared with the blank control group ** P<0.01; compared with the CCl4 group, ## P<0.01; n=5.
[0070] 1.3.4 Scrophularia extract reduces the expression of genes related to fibrosis and collagen deposition in CCl4-induced liver fibrosis mice.
[0071] Acta2 encodes smooth muscle actin (α-SMA), and increased expression of Acta2 represents activation of hepatic stellate cells and is considered a typical marker of liver fibrosis. Col1a1 and Col3a1 are mainly involved in encoding type I and type III collagen, both of which are important components of the extracellular matrix and are hallmark molecules of fibrosis formation.
[0072] The results of the real-time PCR experiment are shown below. Figure 2 Studies have shown that Scrophularia extracts (3.32, 9.95 g / kg) can significantly reduce the expression of CCl4-induced elevated genes such as Acta2, Col1a1, and Col3a1, inhibit hepatic stellate cell activation, and reduce hepatic collagen deposition, thereby improving liver fibrosis.
[0073] In summary, Scrophularia extract can reduce collagen deposition in the liver, decrease the amount of fibrosis markers (HYP, HA, and Col IV) in the liver and serum, inhibit hepatic stellate cell activation, and reduce the expression of genes related to fibrosis and collagen deposition, thereby playing a role in improving liver fibrosis.
[0074] The features mentioned above in this invention, or the features mentioned in the embodiments, can be combined arbitrarily. All features disclosed in this specification can be used in any compositional form, and each feature disclosed in the specification can be replaced by any alternative feature that provides the same, equivalent, or similar purpose. Therefore, unless otherwise specified, the disclosed features are merely general examples of equivalent or similar features.
[0075] The above descriptions are merely embodiments of the present invention, and common knowledge regarding specific structures and characteristics is not elaborated upon here. It should be noted that those skilled in the art can make various modifications and improvements without departing from the present invention, and these should also be considered within the scope of protection of the present invention. These modifications and improvements will not affect the effectiveness of the present invention or the practicality of the patent. The scope of protection claimed by the present invention should be determined by the content of its claims, and the specific embodiments described in the specification can be used to interpret the content of the claims. In conclusion, the content of this specification should not be construed as a limitation of the present invention.
Claims
1. Use of Scrophularia ningpoensis extract in the preparation of drugs for the prevention and treatment of liver fibrosis.
2. The use according to claim 1, characterized in that: The liver fibrosis described herein is characterized by at least one of the following: increased collagen deposition in the liver, elevated hydroxyproline content in liver tissue, elevated serum hyaluronic acid, elevated serum type IV collagen, and increased expression of fibrosis and collagen deposition-related genes.
3. The use according to claim 1, characterized in that: The dosage form of the drug is a pharmaceutically acceptable oral dosage form or injectable formulation.
4. The use according to claim 3, characterized in that: The oral preparations are oral solid preparations and oral liquid preparations; the oral solid preparations are tablets, sustained-release tablets, dispersible tablets, lozenges, capsules, sustained-release capsules, granules, suspensions, drops, and pills; the oral liquid preparations are mixtures, emulsions, suspensions, drops, or syrups; the injectable preparations are injection solutions or powder injections.
5. Use of Scrophularia ningpoensis extract in the preparation of health products that have an auxiliary protective effect against chemically induced liver damage.
6. The use according to claim 5, characterized in that: The aforementioned chemical liver injury is characterized by at least one of the following: increased liver collagen deposition, elevated hydroxyproline content in liver tissue, elevated serum hyaluronic acid, elevated serum type IV collagen, and increased expression of fibrosis and collagen deposition-related genes.
7. The use according to claim 5, characterized in that: The health products mentioned are in pharmaceutically acceptable oral dosage forms; the oral preparations include tablets, lozenges, capsules, granules, suspensions, drops, pills, oral liquids, tea, fruit juice, and beverages.
8. The use according to claim 1 or 2, characterized in that: The aforementioned Scrophularia extract is an aqueous extract or an aqueous alcohol precipitate of Scrophularia.
9. The use according to claim 8, characterized in that: The Scrophularia extract is prepared by the following method: Scrophularia is soaked in water, decocted 2-4 times, filtered, the filtrates are combined, the filtrate is concentrated, water is added to the concentration of crude drug is 0.5-1.5 g / mL, refrigerated, and filtered; or Scrophularia is soaked in water, decocted 2-4 times, filtered, the filtrates are combined, the filtrate is concentrated, ethanol is added to the alcohol content to 20%-70%, allowed to stand, the supernatant is taken, the ethanol is recovered until there is no alcohol odor, then ethanol is added again to the alcohol content to 60%-85%, allowed to stand, the supernatant is taken, the ethanol is recovered until there is no alcohol odor, water is added to the concentration of crude drug is 0.5-1.5 g / mL, refrigerated, and filtered.
10. The use according to claim 8 or 9, characterized in that: The Scrophularia extract is prepared by the following method: Scrophularia is soaked in water, decocted twice, filtered, the filtrates are combined, the filtrate is concentrated, ethanol is added to a concentration of 66%, the mixture is allowed to stand, the supernatant is taken, the ethanol is recovered until there is no alcohol odor, ethanol is added again to a concentration of 80%, the mixture is allowed to stand, the supernatant is taken, the ethanol is recovered until there is no alcohol odor, water is added to a concentration of 0.85 g / mL, the mixture is refrigerated, and then filtered.